EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Prevalence of Neutralizing Autoantibodies Against Type I Interferon in a Multicenter Cohort of Severe or Critical COVID-19 Cases in Shanghai

Dongling Shi, Jie Chen, Meng Zhao, Yuanjia Tang, Chen Zhao, Yinpeng Jin, Di Tian, Yixin Liao, Xuebi Wang, Wei Wang, Xiaohong Fan, Zhigang Yi und 2 weitere

Journal of Clinical Immunology · 2024

DOI: 10.1007/s10875-024-01683-z ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Clinical Immunology, 2024. Verfasst von Dongling Shi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: COVID-19, Interferon Type I. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Sixth People's Hospital of Shanghai, Shanghai Pujiang Program, National Key Research and Development Project of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

We sought to explore the prevalence of type I interferon-neutralizing antibodies in a Chinese cohort and its clinical implications during the Omicron variant wave of SARS-CoV-2.

Methods

Type I interferon (IFN) autoantibodies possessing neutralizing capabilities were identified using luciferase assays. The capacity of the autoantibodies for in vitro interference with antiviral activity of IFN was assessed by using a SARS-CoV-2 replicon system. An analysis of the demographic and clinical profiles of patients exhibiting neutralizing antibodies was also conducted.

Results

In this cohort, 11.8% of severe/critical cases exhibited the existence of type I IFN-neutralizing antibodies, specifically targeting IFN-α2, IFN-ω, or both, with an elderly male patient tendency. Notably, these antibodies exerted a pronounced inhibitory effect on the antiviral activity of IFN against SARS-CoV-2 under controlled in vitro conditions. Furthermore, a noteworthy correlation was discerned between the presence of these neutralizing antibodies and critical clinical parameters, including C-reactive protein (CRP) levels, D-dimer levels, and lymphocyte counts.

Conclusion

The presence of type I IFN-neutralizing antibodies is a pervasive risk factor for severe/critical COVID-19 in the Chinese population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Interferon Type IAgedHumansMaleAutoantibodiesSARS-CoV-2PrevalenceChinaAntibodies, NeutralizingAntiviral Agents

Stichwörter der Autor:innen

COVID-19IFN-α2IFN-ωNeutralizing antibodiesType I interferons

Substanzen

AutoantibodiesAntibodies, NeutralizingInterferon Type IAntiviral Agents

Autor:innen und Institutionen

  • Department of Infectious Diseases, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
  • Scientific Research Center, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
  • Department of Infectious Diseases, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, and Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China.
  • Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine (SJTUSM), Shanghai, China.
  • Liver Disease Center, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.

Förderung

  • the Sixth People's Hospital of Shanghai
  • Shanghai Pujiang Program
  • National Key Research and Development Project of China
  • Three-year Action Plan (2023-2025) and Key Discipline Program on Public Health System Construction of Shanghai
  • the Shanghai "Medical Garden Rising Star" Youth Medical Talent Training Funding Program
  • the Shanghai Hospital Development Center Foundation
  • Shanghai 2020 "Science and Technology Innovation Action Plan" Medical Innovation Research Special

Zitieren

APA

Shi, D., Chen, J., Zhao, M., Tang, Y., Zhao, C., Jin, Y., Tian, D., Liao, Y., Wang, X., Wang, W., Fan, X., Yi, Z., Chen, X., & Ling, Y. (2024). Prevalence of Neutralizing Autoantibodies Against Type I Interferon in a Multicenter Cohort of Severe or Critical COVID-19 Cases in Shanghai. Journal of Clinical Immunology. https://doi.org/10.1007/s10875-024-01683-z

Vancouver

Shi D, Chen J, Zhao M, Tang Y, Zhao C, Jin Y, et al. Prevalence of Neutralizing Autoantibodies Against Type I Interferon in a Multicenter Cohort of Severe or Critical COVID-19 Cases in Shanghai. Journal of Clinical Immunology. 2024. doi:10.1007/s10875-024-01683-z

BibTeX
@article{Shi2024,
  author = {Shi, Dongling and Chen, Jie and Zhao, Meng and Tang, Yuanjia and Zhao, Chen and Jin, Yinpeng and Tian, Di and Liao, Yixin and Wang, Xuebi and Wang, Wei and Fan, Xiaohong and Yi, Zhigang and Chen, Xiaohua and Ling, Yun},
  title = {Prevalence of Neutralizing Autoantibodies Against Type I Interferon in a Multicenter Cohort of Severe or Critical COVID-19 Cases in Shanghai},
  journal = {Journal of Clinical Immunology},
  year = {2024},
  doi = {10.1007/s10875-024-01683-z}
}
Kostenlos starten →